Skip to main content

Health Risks of Counterfeit Pharmaceuticals

Abstract

Pharmaceutical products are not exempt from the practice of counterfeiting. In recent years, many reports have become available demonstrating the presence of fake medicines on the market. Several studies have demonstrated that they are quite often of bad quality.

It is estimated that 5% of all world trade in branded goods is counterfeit, leading to huge financial losses for the pharmaceutical industry. But much more important, from a public health point of view, is that history has shown that such products may lead to a great health risk. The essence of counterfeit products and the reason they are so dangerous is the complete absence of quality control, since they are often indistinguishable from the genuine product.

The existence of counterfeit drugs has long been ignored both by the pharmaceutical industry and by drug regulatory authorities. At present initiatives are being taken, nationally and internationally, to curb counterfeiting. It is now realised that a strong regulatory agency is essential, but the initiatives can only be successful if all parties concerned actively co-operate.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Notes

  1. 1.

    In this article, the terms pharmaceutical product, medicinal product, medicine, and drug are equivalent.

  2. 2.

    A counterfeit medicine is one which is deliberately and fraudulently mislabelled with respect to identity and/or source.[{xc1|1}]

References

  1. 1.

    Counterfeit Drugs. Report of a joint WHO/IFPMA Workshop. Geneva: World Health Organization, 1992

  2. 2.

    The Diethylene Glycol Contamination Prevention Workshop. Co-sponsored by CDC, FDA. Washington, DC: PAHO, 1997

  3. 3.

    Ten Ham M. Counterfeit drugs: implications for health. Adverse Drug React Toxicol Rev 1992; 11(1): 59–65

    PubMed  Google Scholar 

  4. 4.

    Banerjee A. Fake polio vaccine kills 11 children in Nadia [newspaper report]. The Asian Age 1995 Apr 5

    Google Scholar 

  5. 5.

    Cuff R. United Kingdom guidelines on counterfeit drugs. Drug Inf J 1996; 29: 633–7

    Article  Google Scholar 

  6. 6.

    New anticounterfeiting bill strengthens enforcement. Authentication News 2002 Sep; 8 (7)

  7. 7.

    Opinion of the Economic and Social Committee on “Counterfeiting” (2001/C211/02). Official Journal of the European Communities, 2001 Aug 7

  8. 8.

    The Product Surety Center. A resource center for industries and government agencies involved in ensuring the security and safety of products [online]. Available from URL: http://www.productsurety.org [Accessed 2003 Sep 29]

  9. 9.

    LeParc M, editor. Protecting medicines and pharmaceuticals: a manual of anticounterfeiting solutions. Reconnaissance International, 2002 [online]. Available from URL: http://www.reconnaissance-intl.com/reconnaissance/pharma/index.html [Accessed 2003 Set 29]

  10. 10.

    Counterfeit Drugs. Report of the International Workshop on Counterfeit Drugs. Geneva, Switzerland: World Health Organization, 1997

  11. 11.

    Counterfeit Drugs. Guidelines for the development of measures to combat counterfeit drugs. Geneva, Switzerland: World Health Organization, 1999

  12. 12.

    Bruneton C. Qualité des médicaments génériques antituberculeux au Tchad. Réseau Médicaments & Développement (ReMeD) 1997 Dec: 18

    Google Scholar 

  13. 13.

    Wondemagnehu E. Counterfeit and substandard drugs in Myanmar and Viet Nam. Report of a study. Geneva: World Health Organization, 1999 (unpublished document)

    Google Scholar 

  14. 14.

    Poole D. Drug distribution and fake drugs in Nigeria: international workshop. Institute for Medical Informatics. Lagos, Nigeria, 1989

    Google Scholar 

  15. 15.

    Pakistan tackles counterfeits. SCRIP, 1999

  16. 16.

    Vietnam: fake drugs sales down sharply. Marketletter 1998 Jan

Download references

Acknowledgements

The author declares that no funds were received to assist in the preparation of this article. The author has no conflicts of interest directly relevant to the content of this manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Martijn ten Ham.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

ten Ham, M. Health Risks of Counterfeit Pharmaceuticals. Drug-Safety 26, 991–997 (2003). https://doi.org/10.2165/00002018-200326140-00001

Download citation

Keywords

  • Drug Regulatory Authority
  • Counterfeit Drug
  • Counterfeit Product
  • Public Health Point
  • Counterfeit Medicine